Annovis Bio Inc. (ANVS)
Annovis Bio Statistics
Share Statistics
Annovis Bio has 19.49M shares outstanding. The number of shares has increased by 74.43% in one year.
| Shares Outstanding | 19.49M |
| Shares Change (YoY) | 74.43% |
| Shares Change (QoQ) | 41.23% |
| Owned by Institutions (%) | 12.15% |
| Shares Floating | 16.67M |
| Failed to Deliver (FTD) Shares | 19.09K |
| FTD / Avg. Volume | 3.74% |
Short Selling Information
The latest short interest is 2.15M, so 15.56% of the outstanding shares have been sold short.
| Short Interest | 2.15M |
| Short % of Shares Out | 15.56% |
| Short % of Float | 19.54% |
| Short Ratio (days to cover) | 4.31 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -5.59. Annovis Bio's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -5.59 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 0.01 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Annovis Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.
| Current Ratio | 2.72 |
| Quick Ratio | 2.72 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.07B |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -24.59B |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by -85.74% in the last 52 weeks. The beta is 1.65, so Annovis Bio's price volatility has been higher than the market average.
| Beta | 1.65 |
| 52-Week Price Change | -85.74% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 6.54 |
| Relative Strength Index (RSI) | 36.16 |
| Average Volume (20 Days) | 509.9K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -24.59B |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2018.5 |
Balance Sheet
The company has 10.55M in cash and 0 in debt, giving a net cash position of 10.55M.
| Cash & Cash Equivalents | 10.55M |
| Total Debt | 0 |
| Net Cash | 10.55M |
| Retained Earnings | -134.85B |
| Total Assets | 13.93M |
| Working Capital | 10.04M |
Cash Flow
In the last 12 months, operating cash flow was -21.89B and capital expenditures 0, giving a free cash flow of -21.89B.
| Operating Cash Flow | -21.89B |
| Capital Expenditures | 0 |
| Free Cash Flow | -21.89B |
| FCF Per Share | -1797.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ANVS is $25.5, which is 1483.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.5 |
| Price Target Difference | 1483.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -15.32 |
| Piotroski F-Score | 2 |